🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 07373V105
- Market Cap
- Large Cap
- IPO
- 2/6/2020 · $17.00/share
Business: Beam Therapeutics is developing precision genetic medicines through base editing. Founded by leading scientists in CRISPR gene editing, Beam Therapeutics is pursuing therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA.
Company Contact
- CEO
- John Evans
- CFO
- Terry-Ann Burrell
- Headquarters
- 238 Main Street, Cambridge, MA 02139
- Phone
- 857-327-8775
- Investor Relations
- Monique Allaire, Thrust Strategic Communications · 857-327-8775 · monique@thrustsc.com